Investigating Tralokinumab-Related Adverse Events in Treating Atopic Dermatitis: Insights from the FAERS Database
February 2026
in “
Frontiers in Immunology
”
Research cited in this study
5 / 5 resultsresearch Tralokinumab as a Therapeutic Option for Patients with Concurrent Atopic Dermatitis and Alopecia Areata
research Drug-Induced Alopecia After Dupilumab Therapy
Dupilumab may cause significant hair loss, which can reverse after stopping the drug.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research A Novel Therapeutic Paradigm for Patients with Extensive Alopecia Areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing
Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.